Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs. (18th September 2013)

• Record Type: Journal Article
• Authors: Xu, Yan; Johnson, Ana
• Other Names: Göbel Hartmut Academic Editor.
• Is Part Of: Pain research and treatment. Volume 2013(2013)
• Publication Date: 2013-09-18
• Subjects: Pain -- Periodicals; Pain -- Research -- Periodicals; Pain -- Prevention -- Periodicals; Pain -- Treatment -- Periodicals; 616.047205
• DOI: 10.1155/2013/943014
• Languages: English
• ISSNs: 2090-1542

Abstract

Abstract : Chronic non-cancer pain is a debilitating condition associated with high individual and societal costs. While opioid treatment for pain has been available for centuries, it is associated with high variability in outcome, and a considerable proportion of patients is unable to attain relief from symptoms while suffering adverse events and developing medication dependence. We performed a review of the efficacy of pharmacogenomic markers and their abilities to predict adverse events, dependence, and associated economic costs, focusing on two genes: OPRM1 and CYP2D6. Data sources were articles indexed by PubMed on or before August 6, 2013. Articles were first selected after review of their titles and abstracts, and full papers were read to confirm eligibility. Initially, fifty-two articles were identified. Of these, 17 were relevant to biological actions of pharmacogenomic markers and their effect on therapeutic efficacy, 16 to adverse events, 15 to opioid dependence, and eight to economic costs. In conclusion, increasing costs of opioid therapy have made the advances in pharmacogenomics an attractive solution to personalize care with unclear repercussions related to the impact on costs, morbidity, and outcomes. This intersection of pharmacoeconomics and pharmacogenomics presents a unique platform to further examine current advances in clinical medicine and their utility in cost-effective treatment of chronic pain.